Recent advances and emerging therapies in management of dyslipidemias

Pulipati, Vishnu Priya; Davidson, Michael

doi:10.1016/j.tcm.2020.08.007

Cited by 5 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, LDL management is the primary aim in clinical practice to reduce acute CVDs events. Statins, proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors, apolipoprotein A-I-based therapies, and other lipid-lowering therapies have been demonstrated to reduce CVDs events (Zhang et al, 2016;Pulipati and Davidson, 2020). In our study, both TC and LDL-C were significantly decreased by IF treatment, indicating amelioration of hypercholesterolemia is one of the main contributors in the reduction of atherosclerosis.…”

Section: Discussionmentioning

confidence: 56%

Intermittent Fasting Inhibits High-Fat Diet–Induced Atherosclerosis by Ameliorating Hypercholesterolemia and Reducing Monocyte Chemoattraction

Chen

Yan

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Atherosclerosis is a major pathology for cardiovascular diseases (CVDs). Clinically, the intermittent fasting (IF) has been observed to reduce the risk of CVDs. However, the effect of IF on the development of atherosclerosis has not been fully elucidated. Herein, we determined the protection of IF against high-fat diet–induced atherosclerosis in pro-atherogenic low-density lipoprotein receptor deficient (LDLR-/-) mice and the potentially involved mechanisms. The LDLR-/- mice were scheduled intermittent fasting cycles of 3-day HFD feeding ad libitum and 1 day fasting, while the mice in the control group were continuously fed HFD. The treatment was lasted for 7 weeks (∼12 cycles) or 14 weeks (∼24 cycles). Associated with the reduced total HFD intake, IF substantially reduced lesions in the en face aorta and aortic root sinus. It also increased plaque stability by increasing the smooth muscle cell (SMC)/collagen content and fibrotic cap thickness while reducing macrophage accumulation and necrotic core areas. Mechanistically, IF reduced serum total and LDL cholesterol levels by inhibiting cholesterol synthesis in the liver. Meanwhile, HFD-induced hepatic lipid accumulation was attenuated by IF. Interestingly, circulating Ly6Chigh monocytes but not T cells and serum c-c motif chemokine ligand 2 levels were significantly reduced by IF. Functionally, adhesion of monocytes to the aortic endothelium was decreased by IF via inhibiting VCAM-1 and ICAM-1 expression. Taken together, our study indicates that IF reduces atherosclerosis in LDLR-/- mice by reducing monocyte chemoattraction/adhesion and ameliorating hypercholesterolemia and suggests its potential application for atherosclerosis treatment.

show abstract

Section: Discussionmentioning

confidence: 56%

Intermittent Fasting Inhibits High-Fat Diet–Induced Atherosclerosis by Ameliorating Hypercholesterolemia and Reducing Monocyte Chemoattraction

Chen

Yan

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…161 Although the study did not observe a reduction in MACE, the Food and Drug Administration (FDA) granted approval for its use in combination with standard medication for the prevention of MACE in patients with T2M and acute coronary syndrome. 162 Taken together, information on the individual epigenetic profile could advance individualized vascular risk assessment and personalized therapeutic approaches to prevent microvascular disease.…”

Section: Targeting Genetics and Epigeneticsmentioning

confidence: 99%

Mechanisms of Vascular Inflammation and Potential Therapeutic Targets: A Position Paper From the ESH Working Group on Small Arteries

Rios,

de Ciuceis,

Georgiopoulos

et al. 2024

Hypertension

View full text Add to dashboard Cite

Inflammatory responses in small vessels play an important role in the development of cardiovascular diseases, including hypertension, stroke, and small vessel disease. This involves various complex molecular processes including oxidative stress, inflammasome activation, immune-mediated responses, and protein misfolding, which together contribute to microvascular damage. In addition, epigenetic factors, including DNA methylation, histone modifications, and microRNAs influence vascular inflammation and injury. These phenomena may be acquired during the aging process or due to environmental factors. Activation of proinflammatory signaling pathways and molecular events induce low-grade and chronic inflammation with consequent cardiovascular damage. Identifying mechanism-specific targets might provide opportunities in the development of novel therapeutic approaches. Monoclonal antibodies targeting inflammatory cytokines and epigenetic drugs, show promise in reducing microvascular inflammation and associated cardiovascular diseases. In this article, we provide a comprehensive discussion of the complex mechanisms underlying microvascular inflammation and offer insights into innovative therapeutic strategies that may ameliorate vascular injury in cardiovascular disease.

show abstract

A bifunctional anti-PCSK9 scFv/Exendin-4 fusion protein exhibits enhanced lipid-lowering effects via targeting multiple signaling pathways in HFD-fed mice

Xu,

Zhang,

et al. 2023

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Recent advances and emerging therapies in management of dyslipidemias

Cited by 5 publications

References 30 publications

Intermittent Fasting Inhibits High-Fat Diet–Induced Atherosclerosis by Ameliorating Hypercholesterolemia and Reducing Monocyte Chemoattraction

Intermittent Fasting Inhibits High-Fat Diet–Induced Atherosclerosis by Ameliorating Hypercholesterolemia and Reducing Monocyte Chemoattraction

Mechanisms of Vascular Inflammation and Potential Therapeutic Targets: A Position Paper From the ESH Working Group on Small Arteries

A bifunctional anti-PCSK9 scFv/Exendin-4 fusion protein exhibits enhanced lipid-lowering effects via targeting multiple signaling pathways in HFD-fed mice

Contact Info

Product

Resources

About